LNP8701

LNP8701 is an orally active, small molecule inhibitor of Son of Sevenless 1 (SOS1), a guanine nucleotide exchange factor that plays a critical role in the RAS signaling pathway. By blocking SOS1, the drug prevents the conversion of RAS from its inactive GDP-bound state to its active GTP-bound state, thereby inhibiting downstream oncogenic signaling that drives cell proliferation and survival. Developed by Lupin Limited, LNP8701 is being investigated for the treatment of metastatic solid tumors, particularly those with dysregulated RAS signaling. In early clinical studies, it has demonstrated a manageable safety profile and preliminary antitumor activity, including stable disease and partial responses in patients with various advanced cancers such as cervical, breast, and vaginal vault cancers.